GB0720118D0 - Modified mhc class 1 binding peptides - Google Patents

Modified mhc class 1 binding peptides

Info

Publication number
GB0720118D0
GB0720118D0 GBGB0720118.9A GB0720118A GB0720118D0 GB 0720118 D0 GB0720118 D0 GB 0720118D0 GB 0720118 A GB0720118 A GB 0720118A GB 0720118 D0 GB0720118 D0 GB 0720118D0
Authority
GB
United Kingdom
Prior art keywords
mhc class
binding peptides
modified mhc
modified
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0720118.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ACHOUR ADNANE
Leids Universitair Medisch Centrum LUMC
Original Assignee
ACHOUR ADNANE
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ACHOUR ADNANE, Leids Universitair Medisch Centrum LUMC filed Critical ACHOUR ADNANE
Priority to GBGB0720118.9A priority Critical patent/GB0720118D0/en
Publication of GB0720118D0 publication Critical patent/GB0720118D0/en
Priority to PCT/SE2008/051164 priority patent/WO2009051555A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0720118.9A 2007-10-15 2007-10-15 Modified mhc class 1 binding peptides Ceased GB0720118D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0720118.9A GB0720118D0 (en) 2007-10-15 2007-10-15 Modified mhc class 1 binding peptides
PCT/SE2008/051164 WO2009051555A2 (en) 2007-10-15 2008-10-15 Modified mhc class i binding peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0720118.9A GB0720118D0 (en) 2007-10-15 2007-10-15 Modified mhc class 1 binding peptides

Publications (1)

Publication Number Publication Date
GB0720118D0 true GB0720118D0 (en) 2007-11-28

Family

ID=38813830

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0720118.9A Ceased GB0720118D0 (en) 2007-10-15 2007-10-15 Modified mhc class 1 binding peptides

Country Status (2)

Country Link
GB (1) GB0720118D0 (en)
WO (1) WO2009051555A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140284A2 (en) * 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
GB201008682D0 (en) * 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
IL290105B2 (en) 2011-09-15 2024-04-01 Us Health T cell receptors recognizing hla-a1 - or hla-cw7-cw7-restricted mage
CN106999587B (en) 2014-10-02 2023-09-29 希望之城公司 Multivalent mimotopes, mimotope binding antibodies and uses thereof
BR112017016379A2 (en) * 2015-02-18 2018-03-27 Hoffmann La Roche immunoconjugates, composition, peptide use, immunoconjugate use, immunoconjugate generation method, and patient treatment method
CN107624115B (en) 2015-03-16 2021-10-26 加州理工学院 Botulinum neurotoxin specific capture agents, compositions, methods of use, and methods of manufacture
EP3440101B1 (en) * 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
EP3638687A1 (en) 2017-06-15 2020-04-22 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
SG11202005203UA (en) * 2017-12-23 2020-07-29 Rubius Therapeutics Inc Artificial antigen presenting cells and methods of use
CN111886027A (en) * 2017-12-28 2020-11-03 磨石肿瘤生物技术公司 Antigen binding proteins targeting common antigens
CN109293739B (en) * 2018-01-24 2021-03-30 中国疾病预防控制中心病毒病预防控制所 A3 superfamily universal tumor antigen polypeptide and application thereof
MX2021010537A (en) * 2019-03-04 2021-12-10 Univ Health Network T cell receptors and methods of use thereof.
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006202984B2 (en) * 2000-04-04 2009-12-03 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
WO2002072627A2 (en) * 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
WO2003087126A2 (en) * 2002-04-05 2003-10-23 Epimmune Inc. Heteroclitic analogs and related methods
WO2004098526A2 (en) * 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2006002114A2 (en) * 2004-06-17 2006-01-05 Mannkind Corporation Tumor-associated antigen profiles in cancer diagnostics and immunotherapy

Also Published As

Publication number Publication date
WO2009051555A3 (en) 2009-06-04
WO2009051555A2 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
GB0720118D0 (en) Modified mhc class 1 binding peptides
GB2449354B (en) Binding protein
EP2069401A4 (en) Multispecific epitope binding proteins and uses thereof
ZA201004133B (en) Antigen binding proteins
PT2118123E (en) Stabilized p53 peptides and uses thereof
EP2215111A4 (en) Hla-dr binding peptides and their uses
GB0712670D0 (en) Isolated peptides and uses thereof
GB0723712D0 (en) Peptides
EP2180205A4 (en) Ea material
EP2123666A4 (en) Peptide
ZA201006443B (en) Novel immunoregularory peptides,compositions and uses thereof
EP2188305A4 (en) Modified peptides having toxin-enhancing effects
GB0703945D0 (en) Peptide
EP2097439A4 (en) Novel peptides
GB0722399D0 (en) MHC binding peptides and their uses
GB0608139D0 (en) MHC binding peptides and their uses
GB0603336D0 (en) MHC binding peptides and their uses
GB0610452D0 (en) MHC binding peptides and their uses
GB0609896D0 (en) MHC binding peptides and their uses
GB0608138D0 (en) MHC binding peptides and their uses
GB0714346D0 (en) binding peptides
GB0710813D0 (en) Peptides and uses thereof
GB0707626D0 (en) Peptides
GB0705115D0 (en) Peptides
GB0705251D0 (en) Peptides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)